leisure time -WSS

leisure time

author：leisure time 2025-09-27 10:06:09 - browse：55276

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Startup Neumora takes a novel depression drug to Phase 3

WSS

How Medicaid coverage policies for immigrants impact new moms

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Sanders adds drug shortage policies to pandemic preparedness bill

Carvykti CAR

Why health records don't always know when patients are dead

In Spain, a hospital brews its own CAR

hotspot

leisure time

entertainment

Hollywood unions extend contract negotiations for actors

Medicare Advantage beneficiaries sue Humana over algorithm use

Medicare proposal to cover medical devices draws a mixed reaction

Carvykti CAR

Medical records are filled with copy

Can sheer will power keep patients alive in their dying hours?

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Moonlake's readout produced a cash windfall. Risks remain

Biden tests positive for Covid

focus

In early work, researchers turn to CRISPR to treat Alzheimer's

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Sanders adds drug shortage policies to pandemic preparedness bill

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Grail spinoff by Illumina should end disastrous merger attempt

hotspot

hotspot

Wikipedia

explore